1st Biotherapeutics, Inc.

Cmg Pharmaceutical Co., Ltd.

Handok Inc.

Misoon Kim

Jinhwa Lee

Jae Eun Kim

Suyeon Jo

Keonseung Lim

A Yeong Park

Seung Mook Lim

Yejin Hwang

Hwajung Nam

Gadhe Changdev Gorakshnath

Yeonguk Jeon

Inyoung Yang

Minwoo Lee

Moonsoo Kim

Hyang Choi

Jae Il Lee

Jeongbeob Seo

Gilnam Lee

MinWoo Lee

Cheolhwan Yoon

Wanjun Li

Gwibin Lee

Mingzhu Fan

Hyeongjun Kim

Soongyu Choi

Hye Kyoung Kim

Gyooseung Jung

Chaewoon Lee

Cheol Hwan Yoon

Je Hak Kim

Heekyoung Yang

Hyonam Kim

Hankyul Jeong

Kinam Lee

Ki Nam Lee

Jay Hak Kim

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent inflammatory and autoimmune diseases, especially neuroinflammation diseases using the compound.

Compounds for prevention or treatment of neurodegenerative disorders

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.

Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.

Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method for treating or preventing an inflammatory and autoimmune diseases, especially neuroinflammation diseases using the compound.

2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds. 

Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound. 

The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound. 

Benzothiazol compounds and methods using the same for treating neurodegenerative disorders

The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases.  In some compounds of Formula I, Q is &#x2014;CH&#x2550;CRC(O)NRR, &#x2014;C&#x2261;CC(O)NRR, or 

Fused ring heteroaryl compounds and their use as Trk inhibitors

Growing community of inventors

Gyeonggi-do, South Korea

Misoon Kim